Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also develops ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-altered solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-altered solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGRF and RAS/MAPK solid tumors. In addition, the company's products under development include ERAS-801, a central nervous system (CNS)-penetrant EGFR inhibitor for patients with EGFR-altered recurrent glioblastoma (GBM) which is in phase 1 clinical trials; and ERAS-007, an oral inhibitor of ERK1/2 and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It has a license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Erasca Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immunovant (IMVT) and Erasca (ERAS) with bullish sen...

Analysts Offer Insights on Healthcare Companies: Immunovant (IMVT) and Erasca (ERAS)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Erasca (ERAS), Liquidia Technologies (LQDA) and Do...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Erasca (ERAS), Liquidia Technologies (LQDA) and DocGo (DCGO)

An announcement from Erasca ( ($ERAS) ) is now available. On April 27, 2026, Erasca reported positive preliminary Phase 1 dose escalation results f...

Market Cap	$3.21B	P/E Ratio	N/A
52W High	$24.28	52W Low	$1.06
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	39.5%	52W Position	45.0%
Overall Score	39	Value Score	40
Quality Score	34	Technical Score	45

EPS Current Est	$-0.55	EPS Next Est	$-0.55
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ERAS	$11.50	+2.31%	3.17M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ERAS	$11.50	+2.3%	3.17M
3
4
5
6

ERAS

ERAS

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Erasca Inc. Data in Excel

Get Erasca Inc. Data in Excel